Ochre Bio
ochre-bio.comDeveloping therapies for the biggest liver health challenges
Health & Wellnessbiotechliver-diseaserna-therapeuticsdrug-discoveryaigenomicsclinical-pipeline
About
Ochre Bio is a biotech company focused on eliminating the need for liver transplants by developing RNA-based therapies for chronic liver disease. The company uses a Human Discovery Platform that combines proprietary gene perturbation atlases, AI, and human validation models such as perfused livers to identify and validate novel drug targets. Ochre Bio partners with major pharma companies including GSK and Boehringer Ingelheim to advance its pipeline.
Problem
1.5 million people die of liver disease annually and the only curative treatment for most is a liver transplant, of which there is a severe global shortage.
For
pharmaceutical partners and investors in liver disease therapeutics
How it works
Ochre Bio integrates proprietary human liver datasets with AI and human validation models to make causal predictions about drug targets, then develops RNA therapies in-house to rapidly advance candidates through the pipeline.
Business model
unknown
Status
launched
Company
Ochre Bio
Founders
- Quin Willssite